{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:33:39Z","timestamp":1791228819516,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cmi.2026.02.026","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:20:54Z","timestamp":1772850054000},"page":"1052-1059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of the gut microbiome in shaping drug response in immunocompromised hosts"],"prefix":"10.1016","volume":"32","author":[{"given":"Semeh","family":"Bejaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Turroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.02.026_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/187569210792246326","article-title":"The human microbiome project, personalized medicine and the birth of pharmacomicrobiomics","volume":"8","author":"Rizkallah","year":"2010","journal-title":"Curr Pharmacogenomic. Person Med"},{"key":"10.1016\/j.cmi.2026.02.026_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","article-title":"The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism","volume":"14","author":"Spanogiannopoulos","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2026.02.026_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41579-022-00681-5","article-title":"Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota","volume":"20","author":"Lindell","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2026.02.026_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/genes14010055","article-title":"Pharmacomicrobiomics in anticancer therapies: why the gut microbiota should be pointed out","volume":"14","author":"Conti","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.cmi.2026.02.026_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41586-021-03891-8","article-title":"Bioaccumulation of therapeutic drugs by human gut bacteria","volume":"597","author":"Kl\u00fcnemann","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2026.02.026_bib6","doi-asserted-by":"crossref","first-page":"14554","DOI":"10.1038\/srep14554","article-title":"Local bacteria affect the efficacy of chemotherapeutic drugs","volume":"5","author":"Lehouritis","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2026.02.026_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrc.2017.13","article-title":"Microbiota: a key orchestrator of cancer therapy","volume":"17","author":"Roy","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cmi.2026.02.026_bib8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","article-title":"Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects","volume":"45","author":"Daill\u00e8re","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.cmi.2026.02.026_bib9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41564-020-00831-6","article-title":"Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice","volume":"6","author":"Lee","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cmi.2026.02.026_bib11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cancers13050957","article-title":"Bifidobacterium strain-specific enhances the efficacy of cancer therapeutics in tumor-bearing mice","volume":"13","author":"Yoon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cmi.2026.02.026_bib12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1186\/s12967-025-07226-3","article-title":"Fusobacterium nucleatum enhances oxaliplatin resistance in colon cancer by increasing PVT1 expression","volume":"23","author":"Gao","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.cmi.2026.02.026_bib13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/acsinfecdis.7b00166","article-title":"Transformation of the anticancer drug doxorubicin in the human gut microbiome","volume":"4","author":"Yan","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.cmi.2026.02.026_bib15","article-title":"Involvement of abnormal gut microbiota composition and function in doxorubicin-induced cardiotoxicity","volume":"12","author":"Huang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2026.02.026_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41522-025-00712-y","article-title":"Akkermansia muciniphila ameliorates doxorubicin-induced cardiotoxicity by regulating PPAR\u03b1-dependent mitochondrial biogenesis","volume":"11","author":"Lin","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.cmi.2026.02.026_bib17","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/acs.jproteome.0c00230","article-title":"A two-way interaction between methotrexate and the gut microbiota of male Sprague-Dawley rats","volume":"19","author":"Letertre","year":"2020","journal-title":"J Proteome Res"},{"key":"10.1016\/j.cmi.2026.02.026_bib18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib19","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","article-title":"Personalized mapping of drug metabolism by the human gut microbiome","volume":"181","author":"Javdan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2026.02.026_bib20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41564-022-01226-5","article-title":"Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism","volume":"7","author":"Spanogiannopoulos","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cmi.2026.02.026_bib21","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1073\/pnas.1918095117","article-title":"Targeted inhibition of gut bacterial \u03b2-glucuronidase activity enhances anticancer drug efficacy","volume":"117","author":"Bhatt","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2026.02.026_bib22","article-title":"Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats","volume":"7","author":"Lin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2026.02.026_bib23","article-title":"Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites","author":"Hou","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2026.02.026_bib24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.02.026_bib30","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: A phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.02.026_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012659","article-title":"Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial","volume":"13","author":"Hadi","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cmi.2026.02.026_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04186-5","article-title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial","author":"Duttagupta","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.02.026_bib33","doi-asserted-by":"crossref","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2026.02.026_bib34","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","article-title":"Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor","volume":"32","author":"Kim","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cmi.2026.02.026_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04189-2","article-title":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial","author":"Porcari","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.02.026_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.710945","article-title":"Microbiota-host-irinotecan axis: a new insight toward irinotecan chemotherapy","volume":"11","author":"Yue","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2026.02.026_bib37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41570-023-00471-4","article-title":"Targeting the human gut microbiome with small-molecule inhibitors","volume":"7","author":"Woo","year":"2023","journal-title":"Nat Rev Chem"},{"key":"10.1016\/j.cmi.2026.02.026_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.20517\/mrr.2023.23","article-title":"Bifidobacterium in anticancer immunochemotherapy: friend or foe?","volume":"2","author":"Procaccianti","year":"2023","journal-title":"Microbiome Res Rep"},{"key":"10.1016\/j.cmi.2026.02.026_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12916-025-04183-y","article-title":"Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors","volume":"23","author":"Lin","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2026.02.026_bib40","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/2159-8290.CD-24-0066","article-title":"Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity","volume":"14","author":"Glitza","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cmi.2026.02.026_bib41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fcimb.2019.00002","article-title":"The super-donor phenomenon in fecal microbiota transplantation","volume":"9","author":"Wilson","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2026.02.026_bib42","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.cell.2025.04.016","article-title":"The microbiome for clinicians","volume":"188","author":"Porcari","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2026.02.026_bib43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1124\/dmd.118.084772","article-title":"Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites","volume":"47","author":"Guo","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cmi.2026.02.026_bib44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.phrs.2017.03.027","article-title":"Tacrolimus: does direct glucuronidation matter? An analytical and pharmacological perspective","volume":"124","author":"Tron","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cmi.2026.02.026_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s40168-023-01578-y","article-title":"Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1","volume":"11","author":"Degraeve","year":"2023","journal-title":"Microbiome"},{"key":"10.1016\/j.cmi.2026.02.026_bib46","doi-asserted-by":"crossref","first-page":"372.e1","DOI":"10.1016\/j.jtct.2022.04.018","article-title":"Reduced enterohepatic recirculation of mycophenolate and lower blood concentrations are associated with the stool bacterial microbiome after hematopoietic cell transplantation","volume":"28","author":"Saqr","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2026.02.026_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1032290","article-title":"Effects of intestinal microbiota on pharmacokinetics of cyclosporine A in rats","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2026.02.026_bib48","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","volume":"570","author":"Zimmermann","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2026.02.026_bib49","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/TP.0000000000004926","article-title":"Pharmacomicrobiomics: immunosuppressive drugs and microbiome interactions in transplantation","volume":"108","author":"Mohamed","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2026.02.026_bib50","first-page":"S122","article-title":"The gut microbiome and tacrolimus dosing in the peri-heart transplant period","volume":"41","author":"Dela Cruz","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2026.02.026_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eng.2023.09.006","article-title":"Alterations in the gut microbiome in liver recipients with post-transplant diabetes mellitus","volume":"31","author":"Ling","year":"2023","journal-title":"Engineering"},{"key":"10.1016\/j.cmi.2026.02.026_bib52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/cpt.3077","article-title":"Tacrolimus pharmacokinetics is associated with gut microbiota diversity in kidney transplant patients: results from a pilot cross-sectional study","volume":"115","author":"Degraeve","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2026.02.026_bib53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.chroma.2016.10.075","article-title":"A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients","volume":"1475","author":"Tron","year":"2016","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.cmi.2026.02.026_bib54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40495-019-00200-w","article-title":"Microbiome is a functional modifier of P450 drug metabolism","volume":"5","author":"Dempsey","year":"2019","journal-title":"Curr Pharmacol Rep"},{"key":"10.1016\/j.cmi.2026.02.026_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2107289","article-title":"Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate","volume":"14","author":"Simpson","year":"2022","journal-title":"Gut Microbe"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:25:40Z","timestamp":1781195140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1198743X26001047"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.02.026","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of the gut microbiome in shaping drug response in immunocompromised hosts","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}